Skip to main content

Fox Chase Researcher and Former Chief Fellow Presents Findings on 5-Aminolevulinic Acid-Mediated Radiation Therapy to Reduce Tumor Size

Dae-Myoung Yang, PhD presented “Tumor Regression With 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavolt Energies,” during a poster session at the American Society for Radiation Oncology Annual Meeting.
Dae-Myoung Yang, PhD presented “Tumor Regression With 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavolt Energies,” during a poster session at the American Society for Radiation Oncology Annual Meeting.
Dae-Myoung Yang, PhD presented “Tumor Regression With 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavolt Energies,” during a poster session at the American Society for Radiation Oncology Annual Meeting.

 

Radiodynamic therapy at specific energy levels help effectively reduce tumor size in combination with the amino acid 5-aminolevulinic acid, according to findings presented by a Fox Chase Cancer Center researcher recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Diego.

“Radiodynamic therapy is a combined treatment technique of photodynamic therapy and radiation therapy that treats cancer using light and radiation,” said Dae-Myoung Yang, PhD, an Assistant Professor in the Department of Radiation Oncology at Fox Chase.

The study used an in-vivo mouse model to investigate the effectiveness and energy dependency of radiodynamic therapy combined with 5-aminolevulinic acid and different ranges of megavoltage (MV) photon irradiation.

Photon radiation is a tool for treating cancer that uses a linear accelerator to produce high-energy X-rays that damage the DNA inside cancer cells. The naturally occurring amino acid derivative 5-aminolevulinic acid (5-ALA) accumulates in target tumor cells and is metabolized to a photosensitizer, a light absorber that alters the course of a photochemical reaction. This photosensitizer, protoporphyrin IX (PpIX), is activated by high-energy photon beams, which ultimately leads to cellular toxicities that kill malignant tumor cells.

To investigate the effectiveness of different ranges of megavoltage in combination with 5-ALA, Yang and colleagues compared 360 tumors randomized into eight groups. These groups included an untreated control group, a group using 5-ALA only, one group each of 6-, 15-, and 45-MV radiation treatment only, and one group each of 6-, 15-, and 45-MV radiodynamic therapy that consisted of a combination of 5-ALA administration and radiation treatment.

The study demonstrated that using 45 MV photon beam radiation and 5-ALA was more effective in activating PpIX, improving the combined effects of radiation and activated photosensitizer, than the other energy levels tested.

“My research showed improvements in killing tumor tissue and sparing healthy tissues. The preliminary results provide a foundation for new innovative treatment strategies that have the potential to improve cancer treatment,” said Yang.

The results of his study, “Tumor Regression With 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavolt Energies,” were presented during a poster session at the ASTRO meeting. They were also presented at AAPM 2024 in Los Angeles and will be presented at ASTRO 2024 in Washington, DC, in October.